MediPharm Labs Corp.’s facility in Barrie, Ontario, received Good Manufacturing Practice (GMP) certification from Brazil’s National Sanitary Surveillance Agency for the production of finished cannabis goods.
The agency, also known as ANVISA, is the governing body of Brazil’s pharmaceutical industry.
ADVERTISEMENT
In a Wednesday news release, MediPharm said the certification strengthens its position to manufacture both active pharmaceutical ingredients and end products for Brazilian medical cannabis patients.
“This GMP certification from Brazil strengthens MediPharm’s position as one of the most pharmaceutically focused medical cannabis companies in the world,” CEO David Pidduck said in a statement.
“Whether it is the production for cannabis-based drug research, international cannabis medical programs or future marketable cannabis drugs, MediPharm has invested in and executed on the development of global
Read full article on Marijuana Business Daily
